DE60335564D1 - ANTI-INFECTIOUS MEDIUM - Google Patents

ANTI-INFECTIOUS MEDIUM

Info

Publication number
DE60335564D1
DE60335564D1 DE60335564T DE60335564T DE60335564D1 DE 60335564 D1 DE60335564 D1 DE 60335564D1 DE 60335564 T DE60335564 T DE 60335564T DE 60335564 T DE60335564 T DE 60335564T DE 60335564 D1 DE60335564 D1 DE 60335564D1
Authority
DE
Germany
Prior art keywords
compound
hcv
inhibiting
processes
polymerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335564T
Other languages
German (de)
Inventor
John K Pratt
David A Betebenner
Pamela L Donner
Brian E Green
Dale J Kempf
Keith F Mcdaniel
Clarence J Maring
Vincent S Stoll
Rong Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/285,714 external-priority patent/US20040097492A1/en
Priority claimed from US10/625,121 external-priority patent/US20040162285A1/en
Priority claimed from US10/679,881 external-priority patent/US20050075331A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority claimed from PCT/US2003/034707 external-priority patent/WO2004041818A1/en
Application granted granted Critical
Publication of DE60335564D1 publication Critical patent/DE60335564D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an HCV (hepatitis C virus) polymerase inhibiting compound and a composition including a therapeutically effective amount of the compound. <P>SOLUTION: This invention relates to the compound having formula (I). This invention also relates to methods for inhibiting HCV polymerase, inhibiting HCV viral replication, and treating or preventing HCV infection. Processes for making the compounds and the synthetic intermediates employed in the processes, are also provided. <P>COPYRIGHT: (C)2011,JPO&INPIT
DE60335564T 2002-11-01 2003-10-31 ANTI-INFECTIOUS MEDIUM Expired - Lifetime DE60335564D1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/285,714 US20040097492A1 (en) 2002-11-01 2002-11-01 Anti-infective agents
US10/410,853 US20040087577A1 (en) 2002-11-01 2003-04-10 Anti-infective agents
US10/625,121 US20040162285A1 (en) 2002-11-01 2003-07-23 Anti-infective agents
US10/679,881 US20050075331A1 (en) 2003-10-06 2003-10-06 Anti-infective agents
PCT/US2003/034707 WO2004041818A1 (en) 2002-11-01 2003-10-31 Anti-infective agents

Publications (1)

Publication Number Publication Date
DE60335564D1 true DE60335564D1 (en) 2011-02-10

Family

ID=43426110

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335564T Expired - Lifetime DE60335564D1 (en) 2002-11-01 2003-10-31 ANTI-INFECTIOUS MEDIUM

Country Status (6)

Country Link
JP (2) JP4738172B2 (en)
AT (1) ATE493408T1 (en)
DE (1) DE60335564D1 (en)
DK (1) DK1560827T3 (en)
PT (1) PT1560827E (en)
SI (1) SI1560827T1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
GB0800855D0 (en) * 2008-01-17 2008-02-27 Syngenta Ltd Herbicidal compounds
US20090257979A1 (en) * 2008-04-15 2009-10-15 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
MX2011004396A (en) * 2008-10-29 2011-05-25 Basf Se Substituted pyridines having a herbicidal effect.
JP2012519661A (en) * 2009-03-06 2012-08-30 エフ．ホフマン−ラ ロシュ アーゲー Antiviral heterocyclic compounds
WO2011133729A2 (en) * 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
MY183704A (en) * 2011-06-07 2021-03-09 Anadys Pharmaceuticals Inc [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034041A1 (en) * 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
AR036081A1 (en) * 2001-06-07 2004-08-11 Smithkline Beecham Corp COMPOSITE OF 1,2-DIHYDROQUINOLINE, ITS USE TO PREPARE A PHARMACEUTICAL COMPOSITION, METHODS TO PREPARE IT AND N-RENTED 2-AMINOBENZOIC ACID OF UTILITY AS INTERMEDIARY IN SUCH METHODS
WO2003059356A2 (en) * 2001-10-30 2003-07-24 Smithkline Beecham Corporation Novel anti-infectives

Also Published As

Publication number Publication date
JP4738172B2 (en) 2011-08-03
PT1560827E (en) 2011-03-17
JP2011144183A (en) 2011-07-28
DK1560827T3 (en) 2011-04-18
JP2006509042A (en) 2006-03-16
ATE493408T1 (en) 2011-01-15
JP5250649B2 (en) 2013-07-31
SI1560827T1 (en) 2011-04-29

Similar Documents

Publication Publication Date Title
EP2361913A8 (en) Anti-infective agents
WO2007076034A3 (en) Anti-viral compounds
IS8448A (en) Hepatitis C virus inhibition
ID27787A (en) COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES
CO5630024A2 (en) INHIBITING COMPOUNDS OF HEPATITIS C
DE60319820D1 (en) PYRAZOLOE1,5-ATPYRIMIDIN COMPOUNDS AS ANTIVIRAL AGENTS
BR0305259A (en) Hcv ns5b polymerase inhibitors
BRPI0514591A (en) heterocyclic antiviral compounds
EE05709B1 (en) The nucleoside compound, the pharmaceutical composition containing it and its use in the manufacture of a medicament for use as a viral RNA-dependent RNA polymerase inhibitor
HRP20041085B1 (en) Hepatitis c virus inhibitors
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
CR20110153A (en) INHIBITORS OF THE RNA POLYMERASE DEPENDENT ON THE RNA OF THE HEPATITIS C VIRUS AND COMPOSITIONS (DIVISIONAL APPLICATION 8935)
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
BRPI0515596A (en) pharmaceutical composition used for the treatment and / or prevention of hcv, and methods of inhibiting hepatitis c polymerase ns5b from treating or preventing hepatitis c infection in a mammal
WO2004110351A3 (en) Heterocyclic compounds for treating hepatitis c virus
EA200900156A1 (en) Pyridazine compound (VARIANTS), METHOD FOR ITS PREPARATION (VARIANTS), METHOD FOR TREATMENT OR PREVENTION OF VIRAL INFECTION WITH HEPATITIS C USING IT, compositions and medicaments based on its
WO2008133753A3 (en) Anti-viral compounds
HK1100164A1 (en) Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of hcv replication
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
BRPI0415883A (en) nucleoside compounds and compositions for the treatment of viral infections
WO2009069095A3 (en) Antiviral nucleoside compounds
ATE498398T1 (en) CYCLOALKYL HETEROCYCLES FOR THE TREATMENT OF HEPATITIS C VIRUS
DE60335564D1 (en) ANTI-INFECTIOUS MEDIUM
WO2006085141A3 (en) Compositions and methods for treating or preventing hepadnaviridae infection